3rd Annual Spinal Cord Injury Investor Symposium
June 27, 2025 | 8:00am EDT
Click here to listen to the presentation
Phase 1b/2a Chronic Cohort Results
Discussion
June 3, 2025 | 4:15pm EDT
Click here to view presentation
American Spinal Injury Association
Annual Scientific Meeting Presentation
“CONNECT: A 16-week Placebo-controlled Phase 1b/2a
Study of NVG-291: Results for the Chronic Cohort“
June 3, 2025 | 1:40pm EDT
Click here to view Dr. Daniel Mikol’s presentation
2025 Bloom Burton & Co. Healthcare Investor Conference
May 5, 2025 | 10:00am EDT
Click here to listen to the presentation
Virtual Investor Event
To discuss the current spinal cord injury treatment landscape and
NervGen’s Phase 1b/2a trial evaluating NVG-291 in spinal cord injury
April 9, 2025 | 10:00am EDT
Click here to listen to the presentation
Webinar Panel Discussion:
Clinical Research Advancements in Spinal Cord Injury (SCI)
September 5, 2024 | 5:00pm EDT
Click here to listen to the webinar
NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company’s initial target indication, spinal cord injury. NervGen is evaluating a new discovery lead, NVG-300, in a preclinical model of ischemic stroke and confirmatory SCI study.
Contact
112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4
Phone: (778) 731-1711
Email: info@nervgen.com
